Implementation of innovative pharmacogenetic tests into practice in Taiwan: An institutional perspective

Drug Development Research

Volumn 71, Issue 8, 2010, Pages 502-506

  Chen, Hsiang Yin ^a   Chen, Li Chia ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

personalized medicine; pharmacogenetic test; target therapy

Indexed keywords

CLINICAL EDUCATION; CLINICAL PRACTICE; CLINICAL RESEARCH; COST; ECONOMIC EVALUATION; GENETIC SCREENING; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; PHARMACOGENETICS; PROFESSIONAL STANDARD; REVIEW; TAIWAN; TEAMWORK;

EID: 78651109852     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20427     Document Type: Review

References (21)

1. Barlow-Stewart K, Saleh M,. 2007. Pharmacogenetics/pharmacogenomics. Fact Sheet 25. (accessed on 5 October 2010).
2. Cheng TM,. 2003. Taiwan's new national health insurance program: genesis and experience so far. Health Aff 22: 61-76.
3. Deverka PA, McLeod HL,. 2008. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing. Clin Pharmacol Ther 84: 191-193.
4. Evans WE, Relling MV,. 2004. Moving towards individualized medicine with pharmacogenomics. Nature 429: 424-468.
5. Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, Verbrugge RR, Burckart GJ, Lesko LJ,. 2008. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 28: 992-998.
6. Guttmacher AE, Porteous ME, McInerney JD,. 2007. Educating health-care professionals about genetics and genomics. Nat Rev Genet 8: 151-157.
7. Hamburg MAM, Collins FSM,. 2010. The path to personalized medicine. N Engl J Med 363: 301-304.
8. Ikediobi ON, Shin J, Nussbaum RL, Phillips KA,. 2009. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin Pharmacol Ther 86: 28-31.
9. Klotz U,. 2007. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 46: 271-279.
10. Maitland-van der Zee AH, Aitchison K, Kirchheiner J,. 2007. Workshop outcomes report: initiatives to establish a European Network of pharmacogenetics/genomics and progress. Eur J Pharm Sci 31: 151-155.
11. McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, Shapero MH, de Bakker PIW, Maller JB, Kirby A, et al. 2008. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet 40: 1166-1174.
12. Morley K,. 2002. Pharmacogenetics/pharmacogenomics. Fact Sheet 6. (accessed on 5 October 2010).
13. Paci D, Ibarreta D,. 2009. Economic and cost-effectiveness considerations for pharmacogenetics tests: an integral part of translational research and innovation uptake in personalized medicine. Curr Pharmacogenomics Person Med 7: 284-296.
14. Reinhardt UE,. 2008. Humbled in Taiwan. Br Med J 336: 72.
15. Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al. 2009. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328.
16. Secretary's Advisory Committee on Genetic Testing. 2000. Enhancing the oversight of genetic tests: recommendations of the SACGT. (accessed on 29 June 2010).
17. Secretary's Advisory Committee on Genetics, Health and Society. 2008. U.S. system of oversight of genetic testing: a response to the charge of the Secretary of Health and Human Services. (accessed on 29 June 2010).
18. Shin J, Kayser SR, Langaee TY,. 2009. Pharmacogenetics: from discovery to patient care. Am J Health Syst Pharm 66: 625-637.
19. Suther SM, Goodson PP,. 2003. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med 5: 70-76.
20. Valdes Jr R, Payne D, Linder MW,. 2007. Laboratory medicine practice guidelines: laboratory analysis and application of pharmacogenetics to clinical practice. (accessed on 29 June 2010).
21. Watson K, Symmons D, Griffiths I, Silman A,. 2005. The British Society for Rheumatology biologics register. Ann Rheum Dis 64: iv42-iv43.